4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (Nasdaq: FDMT) has announced employment inducement grants for three new non-executive employees. The compensation committee approved the issuance of 16,500 Restricted Stock Units (RSUs) on April 8, 2025.
The RSUs were granted under the Company's 2025 Employment Inducement Award Plan, which was established in February 2025. This plan operates under Rule 5635(c)(4) of The Nasdaq Global Market, specifically designed for equity grants to attract new employees to the company.
4D Molecular Therapeutics (Nasdaq: FDMT) ha annunciato concessioni di indennità per l'impiego per tre nuovi dipendenti non esecutivi. Il comitato per la remunerazione ha approvato l'emissione di 16.500 Unitá Azionarie Riservate (RSUs) l'8 aprile 2025.
Le RSUs sono state concesse nell'ambito del Piano di Indennità per l'Occupazione 2025 dell'azienda, istituito a febbraio 2025. Questo piano opera ai sensi della Regola 5635(c)(4) del Nasdaq Global Market, specificamente progettato per concessioni di azioni al fine di attrarre nuovi dipendenti in azienda.
4D Molecular Therapeutics (Nasdaq: FDMT) ha anunciado concesiones de incentivo para el empleo para tres nuevos empleados no ejecutivos. El comité de compensación aprobó la emisión de 16,500 Unidades de Acciones Restringidas (RSUs) el 8 de abril de 2025.
Las RSUs se otorgaron bajo el Plan de Concesión de Incentivos para el Empleo 2025 de la compañía, que se estableció en febrero de 2025. Este plan opera bajo la Regla 5635(c)(4) del Nasdaq Global Market, diseñado específicamente para otorgar acciones con el fin de atraer nuevos empleados a la empresa.
4D Molecular Therapeutics (Nasdaq: FDMT)는 세 명의 새로운 비임원 직원에 대한 고용 유인 보조금을 발표했습니다. 보상 위원회는 2025년 4월 8일에 16,500 제한주식단위(RSUs)의 발행을 승인했습니다.
이 RSUs는 2025년 2월에 설립된 회사의 2025 고용 유인 보상 계획에 따라 부여되었습니다. 이 계획은 새로운 직원을 회사로 유치하기 위해 특별히 설계된 Nasdaq 글로벌 시장의 규칙 5635(c)(4)에 따라 운영됩니다.
4D Molecular Therapeutics (Nasdaq: FDMT) a annoncé des subventions d'incitation à l'emploi pour trois nouveaux employés non exécutifs. Le comité de rémunération a approuvé l'émission de 16 500 unités d'actions restreintes (RSUs) le 8 avril 2025.
Les RSUs ont été accordées dans le cadre du Plan d'Attribution d'Incentives à l'Emploi 2025 de l'entreprise, qui a été établi en février 2025. Ce plan fonctionne selon la règle 5635(c)(4) du Nasdaq Global Market, conçu spécifiquement pour des attributions d'actions afin d'attirer de nouveaux employés dans l'entreprise.
4D Molecular Therapeutics (Nasdaq: FDMT) hat Beschäftigungsanreize für drei neue nicht-executive Mitarbeiter angekündigt. Der Vergütungsausschuss genehmigte die Ausgabe von 16.500 Restricted Stock Units (RSUs) am 8. April 2025.
Die RSUs wurden im Rahmen des 2025 Beschäftigungsanreizplans des Unternehmens gewährt, der im Februar 2025 eingerichtet wurde. Dieser Plan unterliegt der Regel 5635(c)(4) des Nasdaq Global Market und wurde speziell für Aktienzuteilungen zur Anwerbung neuer Mitarbeiter ins Leben gerufen.
- None.
- None.
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 8, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 16,500 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
How many RSUs did 4DMT (FDMT) grant to new employees in April 2025?
When was 4DMT's 2025 Employment Inducement Award Plan approved?
What is the purpose of FDMT's 2025 Employment Inducement Award Plan?
Under which Nasdaq rule were FDMT's inducement grants approved?
